In the past two decades there has been a tremendous increase in the understanding of the molecular basis of human malignancies. In a variety of neoplasms, specific molecular markers became part of disease classifications and are now routinely used to define specific entities. Molecular analyses discriminate prognostic groups, guide differential treatment strategies and identify targets for molecular defined cancer therapy. A battery of new drugs has been developed to specifically inhibit oncogenic pathways. For an increasing number of solid and haematological malignancies, the availability of molecular targeted drugs has fundamentally changed treatment algorithms. However, the diagnostic, prognostic and therapeutic impact of selected molecular markers is still limited in many cases. After all, the success of a molecular targeted therapy is clearly determined by the significance of the targeted structure for the biology of cancer and the ability of the malignant cell to evade specific inhibition.
or radioiodine in iodine-avid thyroid cancer [3] . More recently, the anti-CD20 monoclonal antibody rituximab [4] and the radioactive-labelled anti-CD20 antibodies ibritumomab tiuxetan [5] and tositumomab [6] have emerged as targeted therapy in CD20 ϩ non-Hodgkin lymphoma.
However, very few malignancies are actually caused and driven by a single or limited number of oncogenic events that combine (bio)marker and target characteristics. One of the rare examples is chronic myelogenous leukaemia (CML), where the t(9;22) (q34;q11) balanced reciprocal translocation generates the Bcr-Abl oncogene that encodes a constitutively active tyrosine kinase. The development of the Abl tyrosine kinase inhibitors (TKI) imatinib
mesylate was facilitated by progress in structure-based drug development and resulted in a highly efficient, well-tolerated therapy that has displaced more aggressive treatment modalities from first line therapy [7] . However, most malignant diseases are driven by a highly complex and plastic survival network that evolves during tumorigenesis. This oncogenic network can rapidly change and adapt during anticancer therapies and progression [8] [9] [10] [11] .
Recently [12, 13] . High throughput DNA sequencing complements this technique in molecular diagnosis and monitoring [14, 15] . Pharmacogenomics correlate gene expression or single nucleotide polymorphisms with drug efficacy or toxicity [16] . Finally [20] , results from a reciprocal translocation between the long arms of chromosomes 9 and 22 [21] , and is present in approximately 95% of CML patients and up to 20% of adult acute lymphoblastic leukaemia (ALL) [22, 23] . The Philadelphia translocation gives rise to the oncogenic Bcr-Abl fusion protein that is characterized by a constitutively active tyrosine kinase. Bcr-Abl is sufficient to cause CML in mice [24] , and its transforming capacity strictly depends on tyrosine kinase activity [25] . This makes Bcr-Abl an attractive target for therapeutic intervention in CML and Ph ϩ ALL.
Techniques used for diagnosis and monitoring of malignant diseases treated with targeted therapies

Sophisticated methods are available today for molecular diagnostics and biomarker identification. Most of these analytical techniques are in the hands of pathologists. High throughput gene expression analysis allows the time efficient acquisition of the whole transcriptome in a given sample
Preclinical and clinical development of the TKI imatinib
The 2-phenylaminopyrimidine class of small-molecule kinase inhibitors was identified using a high throughput screen of compound libraries at Ciba-Geigy (now Novartis, Basel, Switzerland) [26] . The phenylaminopyrimidine CGP57148B (Imatinib-mesylate, hereafter imatinib), a derivative of the initial lead compound, was found to inhibit autophosphorylation of four kinases: The receptor tyrosine kinase platelet-derived growth factor receptor (PDGF-R) ␣ and ␤, the receptor tyrosine kinase cKit and the protein tyrosine kinase Abl, including its close homologue Arg [27, 28] . Imatinib has been demonstrated to specifically inhibit oncogenic derivatives of these kinases including Bcr-Abl [29, 30] and cKit harbouring oncogenic mutations [31] . Preclinical studies demonstrated activity in Bcr-Abl ϩ cell lines and in animal models [26, 29, 32] [69, 70] . In addition, a resistance mutation in the kinase domain of FLT3-ITD in a patient with acute myeloid leukaemia treated with the kinase inhibitor PKC412 has been described [71] . [72, 73] [74] . Like in CML, resistance to imatinib in GIST is associated with mutations in the cKit or PDGFR␣ kinase domain, and second line TKI treatment with sunitinib can be active after imatinib failure [75] .
Similarly, in patients with non-small cell lung cancer (NSCLC) treated with the kinase inhibitor gefitinib, an exchange of threonine at position 790 to methionine in the epidermal growth factor receptor (EGFR) was reported
Therefore, GIST tumours represent an example of a solid tumour entity uniformly addicted to a specific oncogenic kinase (mostly cKit). Molecular diagnostics in GIST can be used for discrimination to other forms of sarcoma (cKit immunohistocehmistry), but also adds valuable prognostic information, as the cKit genotype determines response to imatinib [76]. Similar to GIST in which the survival of the tumour cells strictly depends on a growth factor receptor, other solid tumours with activating mutations in growth factor receptors have been identified. 5-10% of NSCLC patients harbour mutations in the EGFR or METR and show excellent responses to EGFR targeted therapy. In addition, there are a growing number of solid tumours which show amplification of the EGFR. In NSCLC, head and neck and colorectal cancer (CRC) EGFR is a target for already approved and effective molecular therapies.
Treating cancer with EGFR targeting therapy
Cancer is a disease of deregulated cell proliferation and impaired apoptosis [8, 9] [78, 79, 81, 82] . Targeting EGFR mediated cell proliferation and survival is therefore an attractive approach in various solid tumours. The initiation of a growth and survival signalling cascade requires receptor dimerization upon ligand binding, which subsequently leads to phosphorylation of tyrosine kinases and downstream signalling mediators [78, 83, 84] . One signalling step may be the nuclear localization of EGFR [85] . The monoclonal antibody C225 (cetuximab) was identified as a putative therapeutic as it binds the EGFR receptor and blocks subsequently phosphorylation and activation. In a xenotransplant model cetuximab resulted in suppressed growth of human cancer cells [86] . The [127] . Assessment of EGFR copy number by FISH seems to predict for response [128] . [134] . Whether the proposed combinatorial treatment with the BRAF inhibitory TKI sorafenib [135] [80, 136] . The PIK3CA gene is mutated in ~20% of CRC patients [137] [138] (Fig. 2B) .
. The capacity for autonomous and deregulated cell growth as well as inappropriate execution of cell death is often mediated through abnormal expression of growth factor receptors and the constitutive activation of their downstream signalling pathways leading to increased proliferation and survival. Many epithelial cancers are characterized by functional activation of members of the EGFR family [77-79]. EGFR is a transmembrane protein encoded by 28 exons on chromosome 7p12. It is a receptor tyrosine kinase (RTK) and belongs to the Erb family that consists of four closely related members: EGFR (ErbB1), HER-2/neu (ErbB2), Her-3 (ErbB3) and Her-4 (ErbB4). These transmembrane proteins feature an extracellular ligand-binding domain, a membrane-spanning and an intracellular domain. The major signalling pathways activated by EGFR are the RAS-RAF-MAP kinase pathway, which is mainly involved in proliferation, and the PI3K-PTEN-AKT pathway, which is mainly involved in survival [80]. EGFR seems to play an important role in tumorigenesis, since in comparison to normal control tissues, the EGFR gene is frequently found mutated or amplified in cancer. Furthermore, enhanced ligand expression may contribute to activation of EGFR signalling in human cancer
EGFR and KRAS, BRAF and PIK3CA mutations in colorectal cancer
Patients with metastatic colorectal cancer (mCRC) have a 5-year survival rate of less than 10% [121]. The addition of antibody therapy targeting vascular endothelial growth factor (bevacizumab) has significantly improved PFS and OS [122], presumably by inhibiting tumour angiogenesis [123]. Overexpression of EGFR has long been associated with a poor prognosis in CRC [124]. The inhibition of EGFR signalling by the monoclonal antibodies cetuximab or panitumomab has shown activity as a monotherapy and can overcome resistance to standard cytotoxic drugs [121, 125, 126]. Analysis of EGFR expression by immunohistochemistry is not predictive for response to EGFR antibody treatment and patients without EGFR expression as assessed by IHC might respond to cetuximab-based therapy
Interestingly, recent analyses of the RAS-RAF-MAP kinase pathway have shown that mutations downstream of EGFR can bypass EGFR dependence and are actually more informative than EGFR expression data. The presence of mutated KRAS alleles has been demonstrated to be an independent marker for resistance to the anti-EGFR monoclonal antibodies cetuximab and panitumomab [129-132]. Since less than half of the non-responders to these EGFR antibodies display mutant KRAS [129, 131-133] other signalling molecules caught attention as putative mediators of EGFR independence. A recent retrospective analysis revealed that the mutant BRAF V600E allele impairs the therapeutic effect of both approved anti-EGFR antibodies in tumours that display wildtype KRAS, and in fact none of the BRAF V600E-mutant patients responded to antibody treatment
restores sensitivity to EGFR inhibition also in a clinical setting remains to be demonstrated (Fig. 2B). The second major signalling pathway activated by EGFR is the PI3K-PTEN-AKT pathway. PIK3CA encodes for a kinase that mediates EGFR signalling and is kept in check by the tumour suppressor PTEN, which is frequently mutated or deleted in human cancer
and PTEN oncogenic mutations in CRC have been shown to be associated with clinical resistance to panitumomab and cetuximab even in the presence of wild-type KRAS. The authors suggest that a combinatorial molecular assessment of the PTEN-PIK3CA and KRAS pathways may identify the majority of patients unlikely to respond to anti-EGFR antibody treatment
Although these retrospective analyses are of potential great importance for the clinical management of CRC patients a prospective evaluation is urgently needed before implementing such molecular assessments in routine clinical decision-making. Taken together, analysis of the KRAS mutational status in metastatic CRC has become a standard approach to identify patients who will not benefit from EGFR antibody treatment. It is likely that analysis of additional predictive genetic biomarkers that bypass EGFR blockade will become a routine approach in the near future.
Diagnostic use of gene expression analysis: carcinoma of unknown primary
Despite advances in immunohistochemical analysis of tumour biopsies [139] and modern imaging techniques including 2-deoxy-glucose positron emission tomography [140] [145] . Thus, ACUP with a CRC profile is an example of a particular CUP subset that benefits from specific therapy [146] .
Whether the considerable technical requirements for molecular assignment of tissue of origin in cancer of unknown primary will translate in improved treatment responses and prolonged survival however remains to be shown [147] . [148] . This disease is recognized as a distinct entity in the WHO classification of lymphoid neoplasms, but it has been acknowledged that DLBCL comprises genetically heterogenous lymphomas [149] . The introduction of the CD20-targeted monoclonal antibody rituximab into clinical practice has significantly improved progression-free and overall survival in all risk groups [148] . These [151, 154] . A third study identified genes implicated in DLBCL outcome that include B-cell receptor signalling, critical serine/threonine phosphorylation pathways and apoptosis [155] . [155] [156] [157] and fostamatinib disodium, a Syk TKI that might specifically target DLBCL that express a 'B-cell receptor signalling' signature [157, 158] .
With the availability of molecular targeted treatment options this might change though and molecular diagnostics and biomarker identification could concomitantly serve to (i) establish a tissue of origin profile and (ii) determine a treatment modality of first choice including targeted agents.
Prognostic relevance of gene expression analysis: diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in adults
Taken together, results from GEP indicate that in DLBCL pre-treatment gene expression signatures determine outcome. Several of the hereby identified biomarkers could be incorporated into routinely performed IHC or FISH analysis of lymphoma specimens. Examples for phase II/III clinical trials investigating drugs targeting molecular drug targets that were identified by GEP include enzastaurin, a protein kinase C-␤ inhibitor
The challenges in identification of novel prognostic biomarkers in DLBCL include robustness and reproducibility of the techniques (IHC and GEP), as well as availability at reasonable cost. The predictive value of new markers with respect to response to the currently available best treatment, in this case immunochemotherapy, needs to be established. The presumption that DLBCL is a curable disease should not prevent the inclusion of patients into clinical trials that assess new molecular targeted treatments as these treatments might well be associated with less side effects. GEP and other diagnostic tools should allow identification of patients suitable for a specific treatment.
The role of biomarker analysis within clinical trials -involvement of pathologists
Increasing knowledge of the biology of human cancer has provided an enormous number of interesting therapeutic target structures. Drug design has been facilitated by progress in structural analysis of putative target proteins [159] . Switching from chemotherapeutic agents to molecular targeted drugs however may require a different selection of study patients and a different assessment of optimal drug administration as well as efficacy (reviewed in [160, 161] ) and this process involves pathologists at various stages. [96] . This finding was taken as a basis for phase III trials examining first-line TKI treatment in patients with NSCLC harbouring activating EGFR mutations [98] . Second, in a less biased approach, it has been shown that genome-wide screening for receptor tyrosine kinase mutations is feasible [162] . In addition to histopathological and molecular assessment the strategy of selecting patients based on clinical characteristics has been proven efficacious. In the case of NSCLC Asian parentage, female gender, non-or ex-smoking status and adenocarcinoma histology were identified as specific epidmiological markers associated with response to EGFR TKI [95] .
Identification and validation of predictive biomarkers in trials evaluating molecular targeted treatments
Interesting experimental data that may be integrated into prospective clinical trials in the future were derived from the screening of tumour cell lines using an 'integrated genomic profiling' approach [163] . Based on the presumption that distinct genetic lesions create a state of addiction to activated oncogenic signalling pathways [11] , genomically annotated cell lines that represent primary tumours were used to screen compound libraries. KRAS-driven murine lung tumours were found highly susceptible to Heat shock protein (Hsp) 90 inhibitors and tumours with increased v-Abl and SRC copy numbers are greatly sensitive to the Src/Abl TKI dasatinib [163] . Thus, primary cancer genomics using acknowledged cell line profiles could be used to enrich suitable patient subgroups in clinical trials examining molecular targeted drugs in the future (Fig. 3) .
Assessment of optimal drug dose, schedule and treatment combinations
Conventional cytotoxic drugs usually result in a therapeutic effect that is correlated with its toxic effect. The maximum tolerated dose (MTD) is therefore established in phase I clinical trials. This might not be a suitable approach when using targeted drugs since toxic effects and target inhibition could occur at different drug levels or through specific drug schedules [160, 164, 165] . A promising approach of a study design that tries to identify rationally based doses and schedules for targeted cancer treatment has been realized in pharmacodynamic phase I studies. Recent published work uses repeated tumour and normal tissue biopsies to assess the optimal dosage and scheduling of mammalian target of rapamycin (mTOR) inhibiting drugs [166, 167] . mTOR is aberrantly activated in various human cancers and controls cellular proliferation and metabolism [168] . By assessing the inhibition of mTOR downstream events (e.g. phosphorylation of S6 Kinase 1) in tumour biopsies during different dosing and scheduling of everolimus, the dosage-inhibiting mTOR activity was below the previously determined maximum tolerated dose and could be used in future trials [166] . Furthermore, by investigating additional pathways that might be activated upon inhibition of the targeted signal, rational targeted drug combinations can be identified [167] . Pharmacodynamic studies such as biomarker modulation using tumour tissue obtained before and after application of the study drug should therefore be included into early clinical trials whenever technically feasible and appropriate from an ethical point of view (Fig. 3) . 
